Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1997 Sep;71(9):7101–7109. doi: 10.1128/jvi.71.9.7101-7109.1997

Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode.

I Nakano 1, G Maertens 1, M E Major 1, L Vitvitski 1, J Dubuisson 1, A Fournillier 1, G De Martynoff 1, C Trepo 1, G Inchauspe 1
PMCID: PMC192006  PMID: 9261444

Abstract

Plasmids expressing different domains of the hepatis C virus (HCV) envelope E2 glycoprotein from a genotype 1a isolate were constructed to compare the immunogenic potential of E2 in nucleic acid-based immunizations. One plasmid, pCIE2t, expressed a C-terminally truncated form of E2, while others, pS2.SE2A to pS2.SE2E, encoded the adjacent 60-amino-acid (aa) sequences of E2 (inserts A to E) expressed as a fusion with the hepatitis B virus surface antigen. BALB/c mice were given injections of the plasmids intramuscularly (i.m.) or intraepidermally (i.e.) via a gene gun (biolistic introduction), and induced humoral immune responses were evaluated. The i.e. injections resulted in higher seroconversion rates and antibody titers, up to 100-fold, than did the i.m. injections (P = 0.01 to 0.04). Three restricted immunogenic domains, E2A (aa 384 to 443), E2C (aa 504 to 555), and E2E (aa 609 to 674), that yielded antibody titers ranging from 1:59 to > 1:43,700 could be identified. Subtype 1a- and 1b-derived E2 antigens and synthetic peptides were used in Western blot and enzyme-linked immunosorbent assay analyses, which revealed that the cross-reactivity of the plasmid-induced antibodies was linked both to the type of antigen expressed and to the injection mode. Induced anti-E2 antibodies could immunoprecipitate noncovalent E1E2 complexes believed to exist on the surface of HCV virions. This study allowed us to identify restricted immunogenic domains within E2 and demonstrated that different routes of injection of HCV E2 plasmids can result in quantitatively and qualitatively different humoral immune responses.

Full Text

The Full Text of this article is available as a PDF (582.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bos J. D., Kapsenberg M. L. The skin immune system: progress in cutaneous biology. Immunol Today. 1993 Feb;14(2):75–78. doi: 10.1016/0167-5699(93)90062-P. [DOI] [PubMed] [Google Scholar]
  2. Botarelli P., Brunetto M. R., Minutello M. A., Calvo P., Unutmaz D., Weiner A. J., Choo Q. L., Shuster J. R., Kuo G., Bonino F. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology. 1993 Feb;104(2):580–587. doi: 10.1016/0016-5085(93)90430-k. [DOI] [PubMed] [Google Scholar]
  3. Choo Q. L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., Han J., Berger K., Thudium K., Kuo C. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1294–1298. doi: 10.1073/pnas.91.4.1294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  5. Davis H. L., Michel M. L., Whalen R. G. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet. 1993 Nov;2(11):1847–1851. doi: 10.1093/hmg/2.11.1847. [DOI] [PubMed] [Google Scholar]
  6. Delpeyroux F., Chenciner N., Lim A., Malpièce Y., Blondel B., Crainic R., van der Werf S., Streeck R. E. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science. 1986 Jul 25;233(4762):472–475. doi: 10.1126/science.2425433. [DOI] [PubMed] [Google Scholar]
  7. Doe B., Selby M., Barnett S., Baenziger J., Walker C. M. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8578–8583. doi: 10.1073/pnas.93.16.8578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dubuisson J., Hsu H. H., Cheung R. C., Greenberg H. B., Russell D. G., Rice C. M. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol. 1994 Oct;68(10):6147–6160. doi: 10.1128/jvi.68.10.6147-6160.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dubuisson J., Rice C. M. Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin. J Virol. 1996 Feb;70(2):778–786. doi: 10.1128/jvi.70.2.778-786.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Farci P., Alter H. J., Govindarajan S., Wong D. C., Engle R., Lesniewski R. R., Mushahwar I. K., Desai S. M., Miller R. H., Ogata N. Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992 Oct 2;258(5079):135–140. doi: 10.1126/science.1279801. [DOI] [PubMed] [Google Scholar]
  11. Ferrari C., Valli A., Galati L., Penna A., Scaccaglia P., Giuberti T., Schianchi C., Missale G., Marin M. G., Fiaccadori F. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology. 1994 Feb;19(2):286–295. [PubMed] [Google Scholar]
  12. Fournillier Jacob A., Cahour A., Escriou N., Girard M., Wychowski C. Processing of the E1 glycoprotein of hepatitis C virus expressed in mammalian cells. J Gen Virol. 1996 May;77(Pt 5):1055–1064. doi: 10.1099/0022-1317-77-5-1055. [DOI] [PubMed] [Google Scholar]
  13. Fuerst T. R., Niles E. G., Studier F. W., Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8122–8126. doi: 10.1073/pnas.83.21.8122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fuller D. H., Haynes J. R. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res Hum Retroviruses. 1994 Nov;10(11):1433–1441. doi: 10.1089/aid.1994.10.1433. [DOI] [PubMed] [Google Scholar]
  15. Fynan E. F., Webster R. G., Fuller D. H., Haynes J. R., Santoro J. C., Robinson H. L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11478–11482. doi: 10.1073/pnas.90.24.11478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Grakoui A., Wychowski C., Lin C., Feinstone S. M., Rice C. M. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol. 1993 Mar;67(3):1385–1395. doi: 10.1128/jvi.67.3.1385-1395.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Haynes J. R., Fuller D. H., Eisenbraun M. D., Ford M. J., Pertmer T. M. Accell particle-mediated DNA immunization elicits humoral, cytotoxic, and protective immune responses. AIDS Res Hum Retroviruses. 1994;10 (Suppl 2):S43–S45. [PubMed] [Google Scholar]
  18. Higashi Y., Kakumu S., Yoshioka K., Wakita T., Mizokami M., Ohba K., Ito Y., Ishikawa T., Takayanagi M., Nagai Y. Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology. 1993 Dec;197(2):659–668. doi: 10.1006/viro.1993.1641. [DOI] [PubMed] [Google Scholar]
  19. Hoffmann R. M., Diepolder H. M., Zachoval R., Zwiebel F. M., Jung M. C., Scholz S., Nitschko H., Riethmüller G., Pape G. R. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology. 1995 Mar;21(3):632–638. [PubMed] [Google Scholar]
  20. Inchauspe G., Vitvitski L., Major M. E., Jung G., Spengler U., Maisonnas M., Trepo C. Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol. 1997 Feb;16(2):185–195. doi: 10.1089/dna.1997.16.185. [DOI] [PubMed] [Google Scholar]
  21. Jarvis L. M., Watson H. G., McOmish F., Peutherer J. F., Ludlam C. A., Simmonds P. Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis. 1994 Oct;170(4):1018–1022. doi: 10.1093/infdis/170.4.1018. [DOI] [PubMed] [Google Scholar]
  22. Kato N., Ootsuyama Y., Sekiya H., Ohkoshi S., Nakazawa T., Hijikata M., Shimotohno K. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol. 1994 Aug;68(8):4776–4784. doi: 10.1128/jvi.68.8.4776-4784.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kato N., Sekiya H., Ootsuyama Y., Nakazawa T., Hijikata M., Ohkoshi S., Shimotohno K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol. 1993 Jul;67(7):3923–3930. doi: 10.1128/jvi.67.7.3923-3930.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kliks S. C., Shioda T., Haigwood N. L., Levy J. A. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11518–11522. doi: 10.1073/pnas.90.24.11518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kojima M., Osuga T., Tsuda F., Tanaka T., Okamoto H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees. Virology. 1994 Nov 1;204(2):665–672. doi: 10.1006/viro.1994.1582. [DOI] [PubMed] [Google Scholar]
  26. Koshy R., Inchauspé G. Evaluation of hepatitis C virus protein epitopes for vaccine development. Trends Biotechnol. 1996 Oct;14(10):364–369. doi: 10.1016/0167-7799(96)10049-4. [DOI] [PubMed] [Google Scholar]
  27. Lagging L. M., Meyer K., Hoft D., Houghton M., Belshe R. B., Ray R. Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol. 1995 Sep;69(9):5859–5863. doi: 10.1128/jvi.69.9.5859-5863.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Leroux-Roels G., Esquivel C. A., DeLeys R., Stuyver L., Elewaut A., Philippé J., Desombere I., Paradijs J., Maertens G. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfa. Hepatology. 1996 Jan;23(1):8–16. doi: 10.1002/hep.510230102. [DOI] [PubMed] [Google Scholar]
  29. Lesniewski R., Okasinski G., Carrick R., Van Sant C., Desai S., Johnson R., Scheffel J., Moore B., Mushahwar I. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J Med Virol. 1995 Apr;45(4):415–422. doi: 10.1002/jmv.1890450411. [DOI] [PubMed] [Google Scholar]
  30. Lu S., Santoro J. C., Fuller D. H., Haynes J. R., Robinson H. L. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology. 1995 May 10;209(1):147–154. doi: 10.1006/viro.1995.1238. [DOI] [PubMed] [Google Scholar]
  31. Major M. E., Vitvitski L., Mink M. A., Schleef M., Whalen R. G., Trépo C., Inchauspé G. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol. 1995 Sep;69(9):5798–5805. doi: 10.1128/jvi.69.9.5798-5805.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Michel M. L., Davis H. L., Schleef M., Mancini M., Tiollais P., Whalen R. G. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5307–5311. doi: 10.1073/pnas.92.12.5307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Michel M. L., Mancini M., Sobczak E., Favier V., Guetard D., Bahraoui E. M., Tiollais P. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles. Proc Natl Acad Sci U S A. 1988 Nov;85(21):7957–7961. doi: 10.1073/pnas.85.21.7957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Michel M. L., Pontisso P., Sobczak E., Malpièce Y., Streeck R. E., Tiollais P. Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin. Proc Natl Acad Sci U S A. 1984 Dec;81(24):7708–7712. doi: 10.1073/pnas.81.24.7708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Mink M. A., Benichou S., Madaule P., Tiollais P., Prince A. M., Inchauspe G. Characterization and mapping of a B-cell immunogenic domain in hepatitis C virus E2 glycoprotein using a yeast peptide library. Virology. 1994 Apr;200(1):246–255. doi: 10.1006/viro.1994.1182. [DOI] [PubMed] [Google Scholar]
  36. Pertmer T. M., Roberts T. R., Haynes J. R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol. 1996 Sep;70(9):6119–6125. doi: 10.1128/jvi.70.9.6119-6125.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Prince A. M., Brotman B., Huima T., Pascual D., Jaffery M., Inchauspé G. Immunity in hepatitis C infection. J Infect Dis. 1992 Mar;165(3):438–443. doi: 10.1093/infdis/165.3.438. [DOI] [PubMed] [Google Scholar]
  38. Rosa D., Campagnoli S., Moretto C., Guenzi E., Cousens L., Chin M., Dong C., Weiner A. J., Lau J. Y., Choo Q. L. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1759–1763. doi: 10.1073/pnas.93.5.1759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., Watanabe Y., Koi S., Onji M., Ohta Y. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6547–6549. doi: 10.1073/pnas.87.17.6547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Saracco G., Abate M. L., Baldi M., Calvo P. L., Manzini P., Brunetto M. R., Oliveri F., Kuo G., Chien D., Houghton M. Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis. Liver. 1994 Apr;14(2):65–70. doi: 10.1111/j.1600-0676.1994.tb00049.x. [DOI] [PubMed] [Google Scholar]
  41. Sekiya H., Kato N., Ootsuyama Y., Nakazawa T., Yamauchi K., Shimotohno K. Genetic alterations of the putative envelope proteins encoding region of the hepatitis C virus in the progression to relapsed phase from acute hepatitis: humoral immune response to hypervariable region 1. Int J Cancer. 1994 Jun 1;57(5):664–670. doi: 10.1002/ijc.2910570509. [DOI] [PubMed] [Google Scholar]
  42. Tokushige K., Wakita T., Pachuk C., Moradpour D., Weiner D. B., Zurawski V. R., Jr, Wands J. R. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology. 1996 Jul;24(1):14–20. doi: 10.1002/hep.510240104. [DOI] [PubMed] [Google Scholar]
  43. Wagener S., Norley S., zur Megede J., Kurth R., Cichutek K. Induction of antibodies against SIV antigens after intramuscular nucleic acid inoculation using complex expression constructs. J Biotechnol. 1996 Jan 26;44(1-3):59–65. doi: 10.1016/0168-1656(95)00093-3. [DOI] [PubMed] [Google Scholar]
  44. Wang B., Ugen K. E., Srikantan V., Agadjanyan M. G., Dang K., Refaeli Y., Sato A. I., Boyer J., Williams W. V., Weiner D. B. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1993 May 1;90(9):4156–4160. doi: 10.1073/pnas.90.9.4156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Weiner A. J., Brauer M. J., Rosenblatt J., Richman K. H., Tung J., Crawford K., Bonino F., Saracco G., Choo Q. L., Houghton M. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology. 1991 Feb;180(2):842–848. doi: 10.1016/0042-6822(91)90104-j. [DOI] [PubMed] [Google Scholar]
  46. Weiner A. J., Geysen H. M., Christopherson C., Hall J. E., Mason T. J., Saracco G., Bonino F., Crawford K., Marion C. D., Crawford K. A. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3468–3472. doi: 10.1073/pnas.89.8.3468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wolff J. A., Malone R. W., Williams P., Chong W., Acsadi G., Jani A., Felgner P. L. Direct gene transfer into mouse muscle in vivo. Science. 1990 Mar 23;247(4949 Pt 1):1465–1468. doi: 10.1126/science.1690918. [DOI] [PubMed] [Google Scholar]
  48. Xiang Z. Q., Spitalnik S., Tran M., Wunner W. H., Cheng J., Ertl H. C. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology. 1994 Feb 15;199(1):132–140. doi: 10.1006/viro.1994.1105. [DOI] [PubMed] [Google Scholar]
  49. Zibert A., Schreier E., Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology. 1995 Apr 20;208(2):653–661. doi: 10.1006/viro.1995.1196. [DOI] [PubMed] [Google Scholar]
  50. van Doorn L. J., Capriles I., Maertens G., DeLeys R., Murray K., Kos T., Schellekens H., Quint W. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol. 1995 Feb;69(2):773–778. doi: 10.1128/jvi.69.2.773-778.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES